Idorsia Company Profile

✉ Email this page to a colleague

IDORSIA has two approved drugs.

There are eight US patents protecting IDORSIA drugs.

There are one hundred and forty-eight patent family members on IDORSIA drugs in thirty-six countries and twelve supplementary protection certificates in eleven countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes	11,680,058	⤷ Sign Up				⤷ Sign Up
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes	11,174,247	⤷ Sign Up				⤷ Sign Up
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No	9,790,208	⤷ Sign Up	Y	Y		⤷ Sign Up
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes	9,790,208	⤷ Sign Up	Y	Y		⤷ Sign Up
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Taiwan	I510481	⤷ Sign Up
Hong Kong	1208449	⤷ Sign Up
Eurasian Patent Organization	030109	⤷ Sign Up
Eurasian Patent Organization	201401351	⤷ Sign Up
South Korea	101528946	⤷ Sign Up
Taiwan	201835071	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2855453	2290037-7	Sweden	⤷ Sign Up	PRODUCT NAME: DARIDOREXANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR DARIDOREXANT HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1638/001-006 20220502
2855453	2022C/543	Belgium	⤷ Sign Up	PRODUCT NAME: DARIDOREXANT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU/1/22/1638 20220502
2855453	122022000059	Germany	⤷ Sign Up	PRODUCT NAME: DARIDOREXANT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE DARIDOREXANT-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1638 20220429
2855453	C02855453/01	Switzerland	⤷ Sign Up	PRODUCT NAME: DARIDOREXANTUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68481 01.12.2022
2855453	36/2022	Austria	⤷ Sign Up	PRODUCT NAME: DARIDOREXANT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE DARIDOREXANTHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1638 (MITTEILUNG) 20220502
2855453	LUC00279	Luxembourg	⤷ Sign Up	PRODUCT NAME: DARIDOREXANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU 1/22/1638 20220502
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.